Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") ...

WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...

Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from ...

The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...

In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses KITE-363, an anti-CD19/CD20 chimeric antigen receptor T-cell therapy, being studied for patients with ...

The Food and Drug Administration has approved a new, first-of-its-kind semiannual HIV prevention medication, Gilead Sciences ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

The US Food and Drug Administration approves Wednesday, June 18, Gilead Sciences lenacapavir, a twice-yearly injection, for ...

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in metastatic ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...